Abstract
AbstractFIELD was the largest cardiovascular prevention trial using fibrates in type 2 diabetes. Whilst the primary endpoint was not achieved, fenofibrate therapy associated with fewer non‐fatal myocardial infarctions and revascularisation procedures. Progress of renal and retinal microvascular disease appeared to be slowed. Although many patients were also taking statin therapy, FIELD does not provide evidence on efficacy or long‐term safety when co‐prescribed with fibrates. Statin monotherapy remains first line therapy for diabetic dyslipidaemia. Copyright © 2006 John Wiley & Sons, Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
